Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose

H Kenmotsu, Y Tanigawara - Cancer science, 2015 - Wiley Online Library
Docetaxel (Taxotere®) has been one of the most important chemotherapeutic drugs for
cancer treatment since 1996. Although a large number of clinical studies have been …

Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement

FE Stuurman, B Nuijen, JH Beijnen… - Clinical …, 2013 - Springer
The use of oral anticancer drugs has increased during the last decade, because of patient
preference, lower costs, proven efficacy, lack of infusion-related inconveniences, and the …

Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer

S Marsh, J Paul, CR King, G Gifford… - Journal of Clinical …, 2007 - ascopubs.org
Purpose Standard therapy for advanced ovarian cancer consists of a platinum agent in
combination with a taxane, which has a 5-year survival rate of approximately 45%. The large …

Cytochrome P450 in cancer susceptibility and treatment

B Mittal, S Tulsyan, S Kumar, RD Mittal… - Advances in clinical …, 2015 - Elsevier
Abstract Cytochrome 450 (CYP450) designates a group of enzymes abundant in smooth
endoplasmic reticulum of hepatocytes and epithelial cells of small intestines. The main …

[HTML][HTML] Genetics of ABCB1 in Cancer

KT Skinner, AM Palkar, AL Hong - Cancers, 2023 - mdpi.com
Simple Summary Overexpression of ABCB1 has been identified in a wide range of multidrug-
resistant cancers. ABCB1 can become upregulated in many ways, and understanding these …

Pharmacogenetic pathway analysis of docetaxel elimination

SD Baker, J Verweij, GA Cusatis… - Clinical …, 2009 - Wiley Online Library
The purpose of this study was to evaluate the affinity of docetaxel for 14 transporter proteins
and assess the functional significance of 17 variants in five genes involved in drug …

Role of genetic polymorphisms in drug-metabolizing enzyme-mediated toxicity and pharmacokinetic resistance to anti-cancer agents: a review on the …

G Narendra, S Choudhary, B Raju, H Verma… - Clinical …, 2022 - Springer
The inter-individual differences in cancer susceptibility are somehow correlated with the
genetic differences that are caused by the polymorphisms. These genetic variations in drug …

ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel

TM Sissung, CE Baum, J Deeken, DK Price… - Clinical cancer …, 2008 - AACR
Purpose: Polymorphisms that are associated with ABCB1 expression and function may be
linked to treatment efficacy and the development of neutropenia and neurotoxicity in patients …

CYP450 pharmacogenetics for personalizing cancer therapy

RHN van Schaik - Drug Resistance Updates, 2008 - Elsevier
Today's drug therapy regimens rely on the anticipated relation between drug dose, acquired
plasma level and desired effect. However, the capacity of individual patients to absorb and …

[HTML][HTML] Emerging ethnic differences in lung cancer therapy

I Sekine, N Yamamoto, K Nishio, N Saijo - British journal of cancer, 2008 - nature.com
Although global clinical trials for lung cancer can enable the development of new agents
efficiently, whether the results of clinical trials performed in one population can be fully …